Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hypermarcas acquires Neo Quimica

This article was originally published in The Tan Sheet

Executive Summary

Leading Brazilian toiletries maker Hypermarcas looks to expand further in the OTC drug market by offering $751 million for drug firm Neo Quimica. The deal ties in with the firm's strategy to build its brand portfolio in the personal and beauty care sectors as jobs and household income grow in Brazil. The firm has made 24 takeovers since its founding in 2000. Neo Quimica, founded in 1959 and based in Goias, had gross revenue of $217.6 million over the past 12 months. According to the agreement, the Goncalves family, which controls Neo Quimica, will hold two seats on Hypermarcas' nine-member board and will form part of the company's ruling bloc

You may also be interested in...

Biogen’s Recipe For Success In Knowledge Management

Biogen’s “recipe-driven qualification” knowledge management program standardizes data collection and reporting in the laboratory, with efficiency gains of 66%.

Market Intel: Minimally Invasive Procedures Gaining Traction In BPH Treatment Market

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.

Innovo Incontinence Device Goes OTC In US, Labeled To Be Worn For 30 Minutes

Atlantic Therapeutics estimates that one in three women are incontinent, but 60% don’t ask their health care providers about treatment, a statistic that supports offering Innovo OTC less than two years after it launched Rx in the US.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts